Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab in resectable dMMR/MSI-H colon cancer
NCT05855200Phase 3Recruiting
- Sponsor
- GSK
- Start
- Aug 2023
- Primary completion
- Mar 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 28
01
Overview
A Phase 3 trial of dostarlimab in colon cancer, sponsored by GSK. Started Aug 2023; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05855200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05855200.